Research programme: nanopolymer-conjugated anticancer drugs - Rexahn

Drug Profile

Research programme: nanopolymer-conjugated anticancer drugs - Rexahn

Alternative Names: HPMA-docetaxel-folate; HPMA-gemcitabine; Nanopolymer anticancer drugs; RX-21101; RX-21202

Latest Information Update: 28 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Rexahn Pharmaceuticals
  • Class Drug conjugates; Polymers; Pyrimidine nucleosides; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Breast cancer; Non-small cell lung cancer; Ovarian cancer; Prostate cancer

Most Recent Events

  • 26 Oct 2016 Rexahn Pharmaceuticals receives patent from USPTO for targeted delivery of docetaxel directly into cancer tumour cells using a nano-polymer conjugate technology
  • 08 Jun 2015 RX 21101 is still in preclinical trials for Breast cancer, Non-small cell lung cancer, Ovarian cancer and Prostate cancer in USA
  • 21 Apr 2014 Pharmacodynamics and adverse events data from preclinical studies of RX 21101 presented at the 105th Annual Meeting of the American Association for Cancer Research (AACR-2014)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top